Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 2
1980 3
1981 1
1982 5
1983 2
1984 4
1985 6
1986 6
1987 6
1988 12
1989 6
1990 6
1991 7
1992 5
1993 8
1994 8
1995 9
1996 10
1997 9
1998 8
1999 2
2000 3
2001 2
2002 5
2003 5
2004 2
2005 3
2006 3
2007 5
2008 3
2009 5
2010 5
2011 3
2012 4
2013 8
2014 2
2015 4
2016 6
2017 6
2018 6
2019 4
2020 6
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

214 results
Results by year
Filters applied: . Clear all
Page 1
Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
Herrmann H, Sadovnik I, Eisenwort G, Rülicke T, Blatt K, Herndlhofer S, Willmann M, Stefanzl G, Baumgartner S, Greiner G, Schulenburg A, Mueller N, Rabitsch W, Bilban M, Hoermann G, Streubel B, Vallera DA, Sperr WR, Valent P. Herrmann H, et al. Among authors: vallera da. Blood Adv. 2020 Oct 27;4(20):5118-5132. doi: 10.1182/bloodadvances.2020001742. Blood Adv. 2020. PMID: 33085758 Free PMC article.
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.
Sarhan D, Brandt L, Felices M, Guldevall K, Lenvik T, Hinderlie P, Curtsinger J, Warlick E, Spellman SR, Blazar BR, Weisdorf DJ, Cooley S, Vallera DA, Önfelt B, Miller JS. Sarhan D, et al. Among authors: vallera da. Blood Adv. 2018 Jun 26;2(12):1459-1469. doi: 10.1182/bloodadvances.2017012369. Blood Adv. 2018. PMID: 29941459 Free PMC article.
Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager.
Felices M, Lenvik TR, Kodal B, Lenvik AJ, Hinderlie P, Bendzick LE, Schirm DK, Kaminski MF, McElmurry RT, Geller MA, Eckfeldt CE, Vallera DA, Miller JS. Felices M, et al. Among authors: vallera da. Cancer Immunol Res. 2020 Sep;8(9):1139-1149. doi: 10.1158/2326-6066.CIR-19-0837. Epub 2020 Jul 13. Cancer Immunol Res. 2020. PMID: 32661096 Free PMC article.
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, Zhang B, Lenvik AJ, Panoskaltsis-Mortari A, Verneris MR, Tolar J, Cooley S, Weisdorf DJ, Blazar BR, Miller JS. Vallera DA, et al. Clin Cancer Res. 2016 Jul 15;22(14):3440-50. doi: 10.1158/1078-0432.CCR-15-2710. Epub 2016 Feb 4. Clin Cancer Res. 2016. PMID: 26847056 Free PMC article.
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, Miller JS. Gleason MK, et al. Among authors: vallera da. Blood. 2014 May 8;123(19):3016-26. doi: 10.1182/blood-2013-10-533398. Epub 2014 Mar 20. Blood. 2014. PMID: 24652987 Free PMC article.
214 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page